Highlights
- Serum Institute is manufacturing millions of doses of Covishield vaccine
- From April 1, the government has decided to vaccinate all above 45 years
- Currently, Covishied and Covaxin vaccines are being used in India
New Delhi: Pune-based Serum Institute of India CEO Adar Poonawalla on Saturday (March 27) informed that the trials for ‘Covovax’, a vaccine developed by Novavax, have begun in India, and added that he is hoping the vaccine launch will take place by September this year. “Covovax trials finally begin in India; the vaccine is made through a partnership with Novavax and Serum Institute of India. It has been tested against African and UK variants of COVID-19 and has overall efficacy of 89 per cent. Hope to launch by September 2021,” Mr. Poonawalla informed in a tweet.
It may be noted that the SII is already manufacturing millions of doses of Covishield vaccine in technical collaboration with Oxford University and AstraZeneca. In a press statement, Novavax had earlier announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3 per cent, in its Phase three clinical trial conducted in the United Kingdom (UK).
Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #COVID19 and has an overall efficacy of 89%. Hope to launch by September 2021! https://t.co/GyV6AQZWdV
— Adar Poonawalla (@adarpoonawalla) March 27, 2021
The study assessed efficacy during a period with high transmission and with a new UK variant strain of the virus emerging and circulating widely. It was conducted in partnership with the UK government’s Vaccines Taskforce. The country started its vaccination drive on January 16 with priority given to all healthcare and frontline workers in the first phase.
The second phase started on March 1 where doses are being administered to people above the age of 60 and those between 45 and 59 years with specific comorbidities. From April 1, the government has decided to vaccinate all above 45 years. Currently, Covishied and Covaxin vaccines are being used in India.
Also Read: Now, Co-WIN Does Not Schedule Your Appointment For The Second Dose Of COVID-19 Vaccine
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (Water, Sanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollution, waste management, plastic ban, manual scavenging and sanitation workers and menstrual hygiene.
[corona_data_new]
